<DOC>
	<DOCNO>NCT00455013</DOCNO>
	<brief_summary>The purpose clinical research study learn belatacept ( BMS-224818 ) expect show acceptable rate acute rejection ( AR ) steroid-free belatacept-based immunosuppressive regiment compare similar steroid-free tacrolimus regimen . The long-term safety tolerability belatacept base regimen follow long-term administration subject receive kidney transplant</brief_summary>
	<brief_title>A Phase II Study Belatacept ( BMS-224818 ) With Steroid-free Regimen Subjects Undergoing Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Living decease donor renal allograft Men woman , 18 70 year old Subjects receive de novo kidney transplant , complete initial study treatment Month 12 , willing sign inform consent eligible continue long term extension phase Pregnant breastfeed woman Epstein Barr Virus ( EBV ) negative serology First time renal transplant panel reactive antibody ( PRA ) ≥ 50 % retransplantation PRA &gt; 30 % Graft loss due AR Positive Tcell Bcell crossmatch Recipients/donors HIV hepatitis B/C Active tuberculosis ( TB ) Immunosuppressive therapy within 1 year enrollment UNOS ECD organ exclude Body mass index ( BMI ) &gt; 35 kg/m² Subjects develop malignancy ( nonmelanoma skin cancer ) medical condition , investigator 's opinion , treat experimental immunosuppressive drug like belatacept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Kidney transplant</keyword>
</DOC>